Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

Direct access to Wegovy® (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap ...

Q: My doctor is suggesting that I try taking one of those new weight loss drugs -- off-label -- to help me cut down on my alcohol consumption. Does this make any sense? -- Pat R., Ann Arbor, Michigan ...

Expect social and relationships to change after weight loss. The more weight you lose and the more you change your lifestyle to achieve healthy weight loss, the more likely relationships are to change ...